Skip to main content
. 2018 Dec 4;47(4):2011–2028. doi: 10.1093/nar/gky1209

Figure 7.

Figure 7.

FMHM inhibits HCC tumorigenesis and the RPS3/SIRT1 pathway. (A) Chemical structure of FMHM. (B, C) Cytotoxicity analysis of FMHM measured in the HCC cell lines SMMC-7721 and HepG2. (D, E) mRNA and protein levels of RPS3 and SIRT1 in HCC SMMC-7721 and HepG2 cells treated with negative control or FMHM. (F–O) Wound-healing migration (F-G and K-L), cell proliferation (H and M), cell cycle (I and N) and colony formation (J and O) assays were performed in SMMC-7721 and HepG2 cells after treatment with negative control or FMHM. (P) Subcutaneous xenograft of SMMC-7721 cells with or without FMHM treatment. Representative images of the resected subcutaneous tumors from each group are shown. Tumor weights and tumor volumes were measured. *P < 0.05, **P < 0.01, and ***P < 0.001.